[Erectile dysfunction: clinical course with intracavernous PGE1].
OBJECTIVE
The results achieved with PGE1 therapy in 66 patients with erectile dysfunction in our self-injection program are presented.


METHODS
Patients with severe conditions (cancer, infectious disease, renal and hepatic failure, etc.), psychological or hormonal disorders were discarded from the study. All patients were tested with PGE1, the dose was adjusted according to individual response, the patient was instructed how to inject the vasoactive drug and included in the self-injection program. Statistical analysis of the data was performed using the chi-square and the Student 't' test.


RESULTS
The mean follow-up was 9.8 months (range 1-39). Twenty-five patients (37%) withdrew from the program. Six patients (9%) received another treatment due to pain or poor response. A penile prosthesis was implanted in five patients and one patient was treated with a vacuum erection device. Although not statistically significant, local pain was associated with a shorter follow-up. Prolonged erection was also observed but did not influence the length of follow-up.


CONCLUSIONS
Local pain has been associated with a shorter follow-up. A small number of non-responders warranted another therapy.
Ruiz Rubio
J L
JL
Servicio de Urología, Hospital Universitario de Getafe, Madrid, España.
Paez Borda
A
A
Romero Cagigal
R
R
Ruiz de Laroja
J C
JC
Sánchez Sánchez
E
E
Fernández González
I
I
Llorente Abarca
C
C
Berenguer Sánchez
A
A
D000527:Alprostadil / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D014665:Vasodilator Agents / Q000627:therapeutic use*
D014665:Vasodilator Agents; D000527:Alprostadil
Disfunción eréctil: aspectos evolutivos con la PGE1 intracavernosa.